Basic Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 14, 2023; 29(18): 2818-2835
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2818
Table 1 Chromatographic conditions
Time (min)
Parameter
0A: 0%, B: 100%
10A: 50%, B: 50%
13A: 95%, B: 5%
14A: 0%, B: 100%
15A: 0%, B: 100%
Table 2 Primer information
No.
Primer
Sequence (5’ to 3’)
Company
1UREA FGCCAATGGTAAATTAGTTShanghai Invitrogen Biotech Co., Lt
2UREA RCTCCTTAATTGTTTTTAC
3UREB FTCTATCCCTACCCCACAACC
4UREB RCCATCCACGAACACATGGTA
5CagA FACCCCTAGTCGGTAATG
6CagA RGCTTTAGCTTCTGATACTGC
7VacA FGTCAGCATCACACCGCAAC
8VacA RCTGCTTGAATGCGCCAAAC
916sRNA FCTGGAGAGACTAAGCCCTCC
1016sRNA RAGGATCAAGGTTTAAGGATT
Table 3 Antibody information
Name
Art. No.
Company
CagA (A-10)sc-32746Santa Cruz
VacAsc-28368Santa Cruz
m-IgGk BP-HRPsc-516102Santa Cruz
GAPDH AbAF7021Affinity Biosciences
Goat anti-rabbit IgG (H+L) HPRS0001Affinity Biosciences
Table 4 Minimum inhibitory concentration of Banxia Xiexin decoction aqueous extract against Helicobacter pylori (μg/mL)
Strain
Drug-resistanct strain
BXXXT aqueous extract
Berberine
26695Sensitive5121024
G27Sensitive5121024
NSH57Sensitive256512
BHKS159Resistant to levofloxacin, clarithromycin and metronidazole5121024
HPBS001Resistant to levofloxacin, clarithromycin and metronidazole5121024
HPBS002Resistant to metronidazole5121024
HPBS003Resistant to clarithromycin5121024
HPBS004Resistant to levofloxacin5121024
HPBS005Resistant to levofloxacin and metronidazole2561024
HPBS006Resistant to clarithromycin and metronidazole2561024
HPBS007Resistant to clarithromycin5121024
HPBS010Resistant to metronidazole, clarithromycin and levofloxacin 5122048
HPBS011Resistant to metronidazole and clarithromycin5121024
HPBS013Resistant to metronidazole, clarithromycin and levofloxacin5121024
HPBS014Resistant to metronidazole, clarithromycin, amoxicillin and levofloxacin5121024
Table 5 Information of main pharmacodynamic components of Banxia Xiexin decoction aqueous extract
Name
Molecular structural formula
BerberineCOC1=C(OC)C2=C[N+]3=C(C=C2C=C1)C1=CC2=C(OCO2)C=C1CC3
BaicalinC1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O
LuteolinOC1=CC(O)=C2C(=O)C=C(OC2=C1)C1=CC(O)=C(O)C=C1
Gallic acidOC(=O)C1=CC(O)=C(O)C(O)=C1
GingerolCCCCCC(O)CC(=O)CCC1=CC(OC)=C(O)C=C1
WogonosideCOC1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1
Rosmarinic acidOC(=O)[C@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=CC(O)=C(O)C=C1
Aloe-emodinOCC1=CC2=C(C(O)=C1)C(=O)C1=C(C=CC=C1O)C2=O
CatechinCCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O
NaringeninOC1=CC=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
QuercetinOC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
Table 6 Minimum inhibitory concentrations of main antibacterial components in Banxia Xiexin decoction aqueous extract (μg/mL)
Strain
MIC of drugs used alone
MIC of drugs used in combinations
FIC
Effect
BerberineEmodinBerberineEmodin
G2710245122562560.75Addictive
2669510245122561280.50Synergistic
BHKS15910245122561280.50Synergistic
BerberineLuteolinBerberineBerberine
G27102410245125121.00Addictive
26695102410245122560.75Addictive
BHKS159102410245125121.00Addictive
LuteolinGallic acidLuteolinGallic acid
G27102410242562560.50Synergistic
26695102410242562560.50Synergistic
BHKS159102410242562560.50Synergistic
LuteolinRosmarinic acidLuteolinRosmarinic acid
G27102410245122560.75Addictive
26695102410245125121.00Addictive
BHKS159102410245122560.75Addictive
Catechuic acidQuercetinCatechuic acidQuercetin
G27102410245122560.75Addictive
26695102410245122560.75Addictive
BHKS159102410245122560.75Addictive
Catechuic acidEmodinCatechuic acidEmodin
G2710245125122561.00Addictive
2669510245125122561.00Addictive
BHKS15910245122562560.75Addictive
Table 7 Information of related proteins identified by transcriptome analysis after Banxia Xiexin decoction treatment
Uniprot Accession Number
Protein name
Protein amino acid sequence
Pvalue
Reliability
E6NPU2Urease subunit alpha OS = Helicobacter pylori (strain F57), OX = 866346, GN = urea, PE = 3, SV = 1MKLTPKELDKLMLHYAGELARKRKEKGIKLNYVEAVALISAHIMEEARAGKKSAAELMQEGRTLLKPDDVMDGVASMIHEVGIEAMFPDGTKLVTVHTPIESNGKLVPGELFLKNEDITINEGKKAVSVKVKNVGDRPVQIGSHFHFFEVNRCLDFDREKTFGKRLDIASGTAVRFEPGEEKSVELIDIGGNRRIFGFNALVDRQADNESKKIALHRAKERGFHGAKSDDNYVKTIKE0.001211988High
A0A2A6SFH9Urease (fragment) OS = Helicobacter pylori, OX = 210, GN = BB479_08100, PE = 4, SV = 1MKLTPKELDKLMLHYAGELARKRKEKGIKLNYVEAVALIXAHIMEEARAGKKTAAELMQEGRTLLKPDDVMDGVASMIHEVGIEAMFPDGTKLVTVHTXIEANGKLVPGELFLKNEDITINEGKKAVSVKVKNVGDRPVQIGSH0.033815784High
A0A0L0QH58Urease subunit alpha OS = Helicobacter pylori, OX = 210, GN = urea, PE = 3, SV = 1MKLTPKELDKLMLHYAGELAKKRKEKGIKLNYVEAVALISAHIMEEARAGKKSAAELMQEGRTLLKPDDVMDGVASMIHEVGIEAMFPDGTKLVTVHTPIEANGKLVPGELFLKNEDITINEGKKAVSVKVKNVGDRPVQIGSHFHFFEVNRCLDFDREKTFGKRLDIASGTAVRFEPGEEKSVELIDIGGNRRIFGFNALVDRQADNESKKIALHRAKERGFHGAKSDDNYVKTIKE0.033744196High
N4TND2Urease accessory protein UreG OS = Helicobacter pylori Hp A-11, OX = 992035, GN = ureG, PE = 3, SV = 1MVKIGVCGPVGSGKTALIEALTRHMSKDYDMAVITNDIYTKEDAEFMCKNSVMPRERIIGVETGGCPHTAIREDASMNLEAVEEMHGRFPNLELLLIESGGDNLSATFNPELADFTIFVIDVAEGDKIPRKGGPGITRSDLLVINKIDLAPYVGADLKVMERDSKKMRGEKPFIFTNIRAKEGLNDVIAWIKRNALLED0.016839824High
Q8RRP6Cytotoxin associated protein CagA (Fragment), OS = Helicobacter pylori, OX = 210, GN = cagA, PE = 4, SV = 1ALADLKNFSKEQLAQQAQKNESFNAGKKFEFSQSVRNGVNGTLVGNGFSQAEATTLSKNFSDIKKELNAKLGNFNNNNINGLKNSTEPIYAKVNKKETGQAASPEEPIYTQVAKKVNAKIDRLNQIASGLGVVGQAAGFPLKRHDKVDDLSKVGRSVSPEPIYATIDDLGGPFPLKRHDKVDNLSKVGRSVSPEPIYATIDDLGGPFPLKRHDKVDNLSKVGLSRNQELTQKIDNLSQAVSEAKAGFFGNLEQTIDKLKDSTKHNVVNLWAESAKKVPASLSAKLDNYA0.03652953High